DCM
BIOL

DAFNA Capital Management’s Biolase, Inc. BIOL Stock Holding History

DAFNA Capital Management’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-9
Closed -$213K – 51
2013
Q3 		$213K Buy
+9
New +$290K 0.23% 48

Other funds holding BIOL

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PCMI
Princeton Capital Management Inc Princeton, New Jersey $198M AUM 28.98% 1-Year Est. Return
TA
Teton Advisors Rye, New York $142M AUM 42.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DAFNA Capital Management's BIOL Position: Q4 2013 in Review

DAFNA Capital Management sold out of Biolase, Inc. (BIOL) in Q4 2013, closing a stake of 9 shares — an estimated $213K sold.

DAFNA Capital Management first reported a position in BIOL in Q3 2013 and held it in 1 quarter. The position peaked at $213K in Q3 2013. 39 funds tracked by Wall St. Rank hold BIOL as of Q4 2013.

  • DAFNA Capital Management reported no remaining Biolase, Inc. position as of Q4 2013 after selling out during the quarter.
  • DAFNA Capital Management sold 9 Biolase, Inc. shares in Q4 2013, an estimated $213K.
  • DAFNA Capital Management first reported a position in Biolase, Inc. in Q3 2013 and held it in 1 quarter.
  • DAFNA Capital Management's Biolase, Inc. position peaked at $213K in Q3 2013.
  • 39 funds tracked by Wall St. Rank held Biolase, Inc. as of Q4 2013.

Based on DAFNA Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.